Fortress Biotech Company Profile (NASDAQ:FBIO)

About Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech logoFortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:FBIO
  • CUSIP: 21976U10
  • Web: www.coronadobiosciences.com
Capitalization:
  • Market Cap: $193.27 million
  • Outstanding Shares: 50,332,000
Average Prices:
  • 50 Day Moving Avg: $3.62
  • 200 Day Moving Avg: $3.00
  • 52 Week Range: $1.88 - $4.42
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.74
  • P/E Growth: -0.11
Sales & Book Value:
  • Annual Revenue: $60.5 million
  • Price / Sales: 3.19
  • Book Value: $0.95 per share
  • Price / Book: 4.04
Profitability:
  • EBIDTA: ($64,150,000.00)
  • Net Margins: -1,182.49%
  • Return on Equity: -68.82%
  • Return on Assets: -42.47%
Debt:
  • Debt-to-Equity Ratio: 0.37%
  • Current Ratio: 2.55%
  • Quick Ratio: 2.55%
Misc:
  • Average Volume: 194,361 shs.
  • Beta: 1.22
  • Short Ratio: 20.01
 

Frequently Asked Questions for Fortress Biotech (NASDAQ:FBIO)

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

How were Fortress Biotech's earnings last quarter?

Fortress Biotech Inc (NASDAQ:FBIO) released its earnings results on Wednesday, May, 10th. The company reported ($0.30) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.36) by $0.06. The company earned $2.78 million during the quarter, compared to analysts' expectations of $47.04 million. Fortress Biotech had a negative return on equity of 68.82% and a negative net margin of 1,182.49%. View Fortress Biotech's Earnings History.

Where is Fortress Biotech's stock going? Where will Fortress Biotech's stock price be in 2017?

3 analysts have issued twelve-month price objectives for Fortress Biotech's shares. Their forecasts range from $9.00 to $11.00. On average, they expect Fortress Biotech's stock price to reach $10.33 in the next twelve months. View Analyst Ratings for Fortress Biotech.

What are analysts saying about Fortress Biotech stock?

Here are some recent quotes from research analysts about Fortress Biotech stock:

  • 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (5/15/2017)
  • 2. FBR & Co analysts commented, "On May 10, Fortress reported 1Q17 results. The company did not host a conference call, but we had a chance to catch up with the CEO. We note that Fortress made great progress in terms of advancing its pipeline in 2017. Recent company highlights include the launch of two additional subsidiaries in the quarter, Caelum Biosciences and Cyprium Therapeutics, thereby broadening the company pipeline to include amyloid light chain (AL) amyloidosis and Menkes disease indications. We expect the company to continue to advance its pipeline and explore additional opportunities to strengthen its subsidiary company portfolio for the rest of 2017." (5/12/2017)

Who are some of Fortress Biotech's key competitors?

Who owns Fortress Biotech stock?

Fortress Biotech's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.78%), Geode Capital Management LLC (0.57%), ClariVest Asset Management LLC (0.32%), California Public Employees Retirement System (0.25%), Bank of New York Mellon Corp (0.22%) and TIAA CREF Investment Management LLC (0.21%). View Institutional Ownership Trends for Fortress Biotech.

Who sold Fortress Biotech stock? Who is selling Fortress Biotech stock?

Fortress Biotech's stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, TIAA CREF Investment Management LLC, UBS Group AG and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Fortress Biotech.

Who bought Fortress Biotech stock? Who is buying Fortress Biotech stock?

Fortress Biotech's stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., KCG Holdings Inc., Teachers Advisors LLC, Geode Capital Management LLC, Bank of New York Mellon Corp and ClariVest Asset Management LLC. View Insider Buying and Selling for Fortress Biotech.

How do I buy Fortress Biotech stock?

Shares of Fortress Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Fortress Biotech stock cost?

One share of Fortress Biotech stock can currently be purchased for approximately $3.84.

Analyst Ratings

Consensus Ratings for Fortress Biotech (NASDAQ:FBIO) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.33 (169.10% upside)

Analysts' Ratings History for Fortress Biotech (NASDAQ:FBIO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/12/2017FBR & CoReiterated RatingBuy$11.00LowView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$11.00MediumView Rating Details
10/3/2016Roth CapitalInitiated CoverageBuy$9.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Fortress Biotech (NASDAQ:FBIO)
Earnings by Quarter for Fortress Biotech (NASDAQ:FBIO)
Earnings History by Quarter for Fortress Biotech (NASDAQ:FBIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.36)($0.30)$47.04 million$2.78 millionViewN/AView Earnings Details
8/9/2016Q2($0.29)($0.31)$1.07 million$2.23 millionViewN/AView Earnings Details
5/10/2016Q1($0.31)$0.66 millionViewN/AView Earnings Details
3/15/2016Q4($0.09)($0.31)$0.34 millionViewN/AView Earnings Details
11/9/2015Q315($0.13)($0.46)$0.03 millionViewN/AView Earnings Details
8/10/2015Q2($0.16)ViewN/AView Earnings Details
5/11/2015Q1($0.31)ViewN/AView Earnings Details
3/16/2015Q414($0.10)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.17)($0.13)ViewN/AView Earnings Details
5/12/2014Q114($0.18)($0.21)ViewN/AView Earnings Details
3/14/2014Q413($0.22)($0.27)ViewN/AView Earnings Details
11/1/2013Q313($0.31)($0.24)ViewN/AView Earnings Details
8/5/2013Q213($0.31)($0.38)ViewN/AView Earnings Details
5/8/2013Q1 2013($0.30)($0.35)ViewN/AView Earnings Details
3/14/2013Q4 2012($0.27)($0.36)ViewN/AView Earnings Details
11/14/2012Q312($0.28)($0.24)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Fortress Biotech (NASDAQ:FBIO)
2017 EPS Consensus Estimate: ($1.47)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.33)($0.33)($0.33)
Q2 20171($0.37)($0.37)($0.37)
Q3 20171($0.38)($0.38)($0.38)
Q4 20171($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Fortress Biotech (NASDAQ:FBIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Fortress Biotech (NASDAQ:FBIO)
Insider Ownership Percentage: 31.54%
Institutional Ownership Percentage: 14.63%
Insider Trades by Quarter for Fortress Biotech (NASDAQ:FBIO)
Institutional Ownership by Quarter for Fortress Biotech (NASDAQ:FBIO)
Insider Trades by Quarter for Fortress Biotech (NASDAQ:FBIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/16/2016George AvgerinosSVPSell48,912$2.55$124,725.60View SEC Filing  
12/1/2014Lucy LuCFOBuy5,000$1.45$7,250.00View SEC Filing  
11/6/2014Lindsay A Md RosenwaldCEOBuy150,000$1.61$241,500.00View SEC Filing  
11/6/2014Malcolm HoenleinDirectorBuy25,000$1.61$40,250.00View SEC Filing  
11/6/2014Michael S WeissMajor ShareholderBuy1,000,000$1.61$1,610,000.00View SEC Filing  
6/2/2014Lucy LuCFOBuy5,000$1.37$6,850.00View SEC Filing  
4/22/2014Kevin HorganInsiderSell47,566$1.89$89,899.74View SEC Filing  
4/21/2014Kevin HorganInsiderSell19,000$1.81$34,390.00View SEC Filing  
8/21/2013J Jay LobellDirectorBuy5,000$7.37$36,850.00View SEC Filing  
7/17/2013Lucy LuCFOBuy4,545$7.90$35,905.50View SEC Filing  
6/20/2013J Jay LobellDirectorBuy10,000$7.62$76,200.00View SEC Filing  
5/31/2013Dale RitterCAOBuy1,503$3.88$5,831.64View SEC Filing  
5/31/2013Lucy LuCFOBuy4,979$3.88$19,318.52View SEC Filing  
5/31/2013Noah D BeermanCOOBuy5,000$3.88$19,400.00View SEC Filing  
1/14/2013Harlan F WeismanCEOBuy20,000$5.71$114,200.00View SEC Filing  
11/30/2012Glenn L Md CooperInsiderBuy3,811$4.02$15,320.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Fortress Biotech (NASDAQ:FBIO)
Latest Headlines for Fortress Biotech (NASDAQ:FBIO)
Source:
DateHeadline
finance.yahoo.com logoAvenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol
finance.yahoo.com - May 19 at 4:53 PM
finance.yahoo.com logoFortress Biotech (FBIO) Looks Good: Stock Adds 5% in Session
finance.yahoo.com - May 19 at 4:53 PM
americanbankingnews.com logoFortress Biotech Inc (FBIO) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 15 at 8:58 PM
finance.yahoo.com logoETFs with exposure to Fortress Biotech, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 4:49 PM
finance.yahoo.com logoMustang Bio Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - May 15 at 4:48 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Fortress Biotech Inc (FBIO) Boosted by FBR & Co
www.americanbankingnews.com - May 15 at 7:58 AM
finance.yahoo.com logoFortress Biotech, Inc. :FBIO-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 5:41 PM
americanbankingnews.com logoFortress Biotech Inc (FBIO) Receives Buy Rating from FBR & Co
www.americanbankingnews.com - May 12 at 5:20 PM
americanbankingnews.com logoFortress Biotech Inc (FBIO) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 7:36 PM
finance.yahoo.com logoFortress Biotech Reports First Quarter 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - May 10 at 5:15 PM
finance.yahoo.com logoFortress Biotech reports 1Q loss
finance.yahoo.com - May 10 at 5:15 PM
finance.yahoo.com logoFortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis
finance.yahoo.com - May 4 at 12:30 PM
americanbankingnews.com logoFortress Biotech (FBIO) Receiving Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - May 1 at 4:48 PM
finance.yahoo.com logoFortress Biotech to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.
finance.yahoo.com - April 27 at 11:24 AM
finance.yahoo.com logoCheckpoint Therapeutics to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co.
finance.yahoo.com - April 27 at 11:24 AM
americanbankingnews.com logoFortress Biotech (FBIO) Getting Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - April 24 at 10:46 AM
finance.yahoo.com logoMustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
finance.yahoo.com - April 24 at 8:19 AM
americanbankingnews.com logoFortress Biotech (FBIO) Earning Negative Press Coverage, Report Shows
www.americanbankingnews.com - April 20 at 8:49 AM
americanbankingnews.com logoFortress Biotech (FBIO) Earning Very Positive News Coverage, Report Shows
www.americanbankingnews.com - April 16 at 8:10 AM
seekingalpha.com logoFortress Biotech (FBIO) Presents At The 24th Annual Future Leaders in the Biotech Industry Conference - Slideshow
seekingalpha.com - April 10 at 4:55 PM
americanbankingnews.com logoFortress Biotech's (FBIO) "Buy" Rating Reiterated at FBR & Co
www.americanbankingnews.com - April 7 at 10:07 PM
finance.yahoo.com logoCheckpoint Therapeutics Reports Preclinical Data for Two Oncology Programs
finance.yahoo.com - April 7 at 9:45 AM
finance.yahoo.com logoFortress Biotech Announces Orphan Drug Designations for CAEL-101 in Amyloidosis
finance.yahoo.com - April 7 at 9:45 AM
finance.yahoo.com logoFortress Biotech to Present at BioCentury’s 24th Annual Future Leaders in the Biotech Industry Conference
finance.yahoo.com - March 30 at 5:36 PM
americanbankingnews.com logoFortress Biotech Inc (FBIO) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 27 at 8:26 AM
finance.yahoo.com logoFORTRESS BIOTECH, INC. Financials
finance.yahoo.com - March 23 at 5:38 PM
americanbankingnews.com logoFortress Biotech Inc (FBIO) Now Covered by Analysts at JMP Securities
www.americanbankingnews.com - March 22 at 11:07 PM
finance.yahoo.com logoCoverage initiated on Fortress Biotech by JMP Securities
finance.yahoo.com - March 22 at 5:18 PM
americanbankingnews.com logoFortress Biotech Inc (FBIO) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 21 at 10:39 PM
finance.yahoo.com logoFortress Biotech Reports Financial Results for the Fourth Quarter and Full Year Ended December 31, 2016
finance.yahoo.com - March 16 at 6:30 PM
biz.yahoo.com logoFORTRESS BIOTECH, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex
biz.yahoo.com - March 16 at 6:30 PM
streetinsider.com logoFortress Biotech (FBIO) Announces New Subsidiary, Cyprium Therapeutics
www.streetinsider.com - March 14 at 12:44 PM
finance.yahoo.com logo7:31 am Fortress Biotech announces formation of a new subsidiary, Cyprium Therapeutics; as part of the formation, co has entered into a CRADA w/ the NIH to advance the clinical development of Phase 3 candidate CUTX-101 for the treatment of
finance.yahoo.com - March 14 at 12:44 PM
americanbankingnews.com logoFortress Biotech Inc (FBIO) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - March 10 at 11:10 PM
seekingalpha.com logoA Profitable Microcap Trading At Less Than 10% Of Revenues, Acquisition Target, No Wall St. Coverage
seekingalpha.com - March 10 at 11:20 AM
finance.yahoo.com logoFortress Biotech to Present at the 29th Annual ROTH Conference
finance.yahoo.com - March 9 at 5:37 PM
finance.yahoo.com logoCheckpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lung Cancer Compound CK-101
finance.yahoo.com - February 28 at 8:28 AM
biz.yahoo.com logoFORTRESS BIOTECH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - February 8 at 5:38 PM
finance.yahoo.com logoFortress Biotech Announces that its Subsidiary, Mustang Bio, Closes $94.5 Million Private Placement Financing - Yahoo Finance
finance.yahoo.com - February 4 at 5:15 PM
us.rd.yahoo.com logoFortress Biotech Announces that its Subsidiary, Mustang Bio, Closes $94.5 Million Private Placement Financing
us.rd.yahoo.com - February 2 at 5:39 PM
us.rd.yahoo.com logoNational Holdings’ OPN Capital Markets Closes $94.5 Million Private Placement Financing for Mustang Bio, Inc., a Subsidiary of Fortress Biotech
us.rd.yahoo.com - February 2 at 5:39 PM
us.rd.yahoo.com logoFortress Biotech Forms New Subsidiary, Caelum Biosciences, Inc., to Develop Novel Treatment for AL Amyloidosis
us.rd.yahoo.com - January 4 at 6:17 PM
biz.yahoo.com logoFORTRESS BIOTECH, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - January 4 at 12:23 AM
us.rd.yahoo.com logo8:19 am Fortress Biotech receives NOAs from the USPTO for two patent applications that cover methods of administration for its lead product candidate intravenous tramadol
us.rd.yahoo.com - January 3 at 7:23 PM
streetinsider.com logoPre-Open Stock Movers 12/29: (FBIO) (MARK) (SHLD) Higher; (CEMP) (APTO) (NVDA) Lower (more...)
www.streetinsider.com - December 30 at 3:20 AM
streetinsider.com logoUnusual 11 Mid-Day Movers 12/29: (KOOL) (FBIO) (MBLY) Higher; (CEMP) (IDXG) (LIVE) Lower (more...)
www.streetinsider.com - December 29 at 10:19 PM

Social

Chart

Fortress Biotech (FBIO) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff